['hepatitis c']
['daclatasvir', 'asunaprevir']

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients chronically infected with HCV Genotype 1b

          -  No previous exposure to any interferon formulation, Ribavirin (RBV), and HCV direct
             acting antiviral agent

          -  HCV RNA viral load ≥ 10,000 IU/mL at screening

          -  Seronegative for HIV and HBsAg

          -  BMI of 18-35 kg/m2, inclusive

          -  Patients with compensated cirrhosis are permitted

        Exclusion Criteria:

          -  Infection with HCV other than genotype (GT) -1b

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV

          -  Diagnosed or suspected hepatocellular carcinoma or other malignancies

          -  Uncontrolled diabetes or hypertension

          -  History of moderate to severe depression. Well-controlled mild depression is allowed

          -  Confirmed alanine aminotransferase (ALT) ≥ 5x Upper Limit of Normal (ULN)

          -  Confirmed platelet count < 50,000 cells/mm3

          -  Confirmed hemoglobin < 8.5 g/dL
      